NVCR News and Press, NovoCure Limited From 01/02/20

Baxter International (NYSE: BAX ) upgraded to Outperform with a $94 (12% upside) price target at Evercore ISI. Shares up  1%  premarket. More news on: Baxter International Inc., Henry Schein, Inc., Medtronic plc, Healthcare stocks news, Stocks on the move, , Read more ...

Novocure (NASDAQ: NVCR) will participate in the 38 th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to prese...

NovoCure Limited (NVCR) is a ~$7.9 billion market capitalization oncology device company that provides patients with a new cancer treatment based on alternating electric field technology. The company's lead product is based on the research work of founder Yoram Palti that such electric fields,...

Larry Culp is a Builder of Corporations, Not a Caretaker We've all heard the nostrum "The best defense is a good offense". The best way for General Electric (GE) to dig out of its liabilities is to change the growth profile and boost cash flow. The opportunity to gather revenue-generating ...

SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its Board of Directors, effective imme...

Shares of NovoCure  (NASDAQ: NVCR) , which makes devices for treating cancerous solid tumors with electric fields, rocketed 28.7% last month, according to data from  S&P Global Market Intelligence . For context, the S&P 500 returned 3.6% in November. The  healthc...

The program includes research grants and career development awards totaling more than $2 million over the next three years Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2 nd Annual AACR-Novocure Grants for Tumor Treating Fields Re...

Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure’s Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr. Doyle’s presentation will begin at 12:30 p.m. EST. Mr. Doyle will also participate in ...

Background Cancers of the brain (gliomas) are rare, yet fast-growing and deadly. Per a thorough 2017 study , the incidence rate is 22.64 Americans per 100,000 population. Although there has been some success with NovoCure's (NVCR) Optune system (more on this later), multiple recent drug t...

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...